CN114615983A - 儿科曲唑酮组合物及其治疗方法 - Google Patents

儿科曲唑酮组合物及其治疗方法 Download PDF

Info

Publication number
CN114615983A
CN114615983A CN202080066712.7A CN202080066712A CN114615983A CN 114615983 A CN114615983 A CN 114615983A CN 202080066712 A CN202080066712 A CN 202080066712A CN 114615983 A CN114615983 A CN 114615983A
Authority
CN
China
Prior art keywords
trazodone
pediatric
dose
pharmaceutical composition
ndd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080066712.7A
Other languages
English (en)
Chinese (zh)
Inventor
F·卡利斯蒂
L·拉格尼
S·托吉亚尼
R·皮克洛
L·欧格基亚努
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Angelini Ag
Original Assignee
Angelini Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angelini Ag filed Critical Angelini Ag
Publication of CN114615983A publication Critical patent/CN114615983A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202080066712.7A 2019-09-26 2020-09-25 儿科曲唑酮组合物及其治疗方法 Pending CN114615983A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962906166P 2019-09-26 2019-09-26
US62/906,166 2019-09-26
PCT/EP2020/077017 WO2021058810A1 (en) 2019-09-26 2020-09-25 Pediatric trazodone compositions and method of treatment thereof

Publications (1)

Publication Number Publication Date
CN114615983A true CN114615983A (zh) 2022-06-10

Family

ID=72665264

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080066712.7A Pending CN114615983A (zh) 2019-09-26 2020-09-25 儿科曲唑酮组合物及其治疗方法

Country Status (13)

Country Link
US (1) US12514856B2 (enExample)
EP (1) EP4034117A1 (enExample)
JP (1) JP7629453B2 (enExample)
KR (1) KR102936358B1 (enExample)
CN (1) CN114615983A (enExample)
AU (1) AU2020354534B2 (enExample)
BR (1) BR112022005343A2 (enExample)
CA (1) CA3153639A1 (enExample)
GE (2) GEP20257739B (enExample)
IL (1) IL291548A (enExample)
MX (1) MX2022003442A (enExample)
UA (1) UA129270C2 (enExample)
WO (1) WO2021058810A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240173315A1 (en) * 2022-11-14 2024-05-30 OWP Pharmaceuticals, Inc. Trazodone oral solution
US20240390277A1 (en) * 2023-04-15 2024-11-28 Rubicon Research Private Limited Liquid formulations of trazodone
CN119280155B (zh) * 2024-12-11 2025-02-25 新基元(北京)医药科技有限公司 一种改善稳定性的盐酸曲唑酮液体药物组合物及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009016069A2 (en) * 2007-07-31 2009-02-05 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. Stable liquid pharmaceutical composition based on trazodone

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1931346T1 (sl) 2005-09-09 2012-10-30 Angelini Labopharm Llc Trazodonski sestavek za dajanje enkrat dnevno
ITMI20071603A1 (it) 2007-08-03 2009-02-04 Acraf Trazodone e trazodone cloridrato in forma purificata

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009016069A2 (en) * 2007-07-31 2009-02-05 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. Stable liquid pharmaceutical composition based on trazodone

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ALLISON BECK BLACKMER ET AL: ""Management of Sleep Disorders in Children With Neurodevelopmental Disorders: A Review"", 《PHARMACOTHERAPY》, vol. 36, no. 1, pages 84, XP055758040, DOI: 10.1002/phar.1686 *
OLIVIERO BRUNI, ET AL: ""Practitioner Review: Treatment of chronic insomnia in children and adolescents with neurodevelopmental disabilities"", 《JOURNAL OF CHILD PSYCHOLOGY AND PSYCHIATRY 》, vol. 59, no. 5, 30 April 2018 (2018-04-30), pages 2, XP009524511, DOI: 10.1111/jcpp.12812 *
OLIVIERO BRUNI, ET AL: ""Practitioner Review: Treatment of chronic insomnia in children and adolescents with neurodevelopmental disabilities"", 《JOURNAL OF CHILD PSYCHOLOGY AND PSYCHIATRY》, vol. 59, no. 5, pages 489, XP009524511, DOI: 10.1111/jcpp.12812 *

Also Published As

Publication number Publication date
JP2022549473A (ja) 2022-11-25
IL291548A (en) 2022-05-01
JP7629453B2 (ja) 2025-02-13
CA3153639A1 (en) 2021-04-01
GEAP202415936A (en) 2024-10-28
WO2021058810A1 (en) 2021-04-01
MX2022003442A (es) 2022-07-11
BR112022005343A2 (pt) 2022-06-14
GEP20257739B (en) 2025-02-25
US12514856B2 (en) 2026-01-06
KR102936358B1 (ko) 2026-03-10
EP4034117A1 (en) 2022-08-03
KR20220080096A (ko) 2022-06-14
US20220331312A1 (en) 2022-10-20
UA129270C2 (uk) 2025-03-05
AU2020354534B2 (en) 2025-10-02
AU2020354534A1 (en) 2022-04-14

Similar Documents

Publication Publication Date Title
EP2678320B1 (en) Flumazenil complexes, compositions comprising same and uses thereof
JP7629453B2 (ja) 小児用トラゾドン組成物およびその治療法
JP2025003983A (ja) うつ病の治療のためのエスケタミン
CN110035741B (zh) 包含托莫西汀盐酸盐的口服溶液及其方法
AU2013323435A1 (en) Apixaban liquid formulations
Marçon et al. Population pharmacokinetic evaluation of ADV6209, an innovative oral solution of midazolam containing cyclodextrin
Nielsen et al. Topical morphine for oral mucositis in children: dose finding and absorption
KR20130099140A (ko) 베포타스틴 조성물
Dao et al. Novel Patient‐Friendly Orodispersible Formulation of Ivermectin is Associated With Enhanced Palatability, Controlled Absorption, and Less Variability: High Potential for Pediatric Use
JP6410814B2 (ja) フェキソフェナジンを含む経口投与用液体医薬組成物
CN114302724A (zh) 用于治疗镰状细胞病的pde9抑制剂
US20220370390A1 (en) Liquid oral formulation of bumetanide
Li et al. Pediatric cardiovascular drug trials, lessons learned
US20250057789A1 (en) Stable oral liquid formulations containing metoprolol or salts thereof
EA047917B1 (ru) Композиции тразодона для применения в педиатрии и способ лечения ими
Sawant et al. A randomized pilot study to evaluate the stability, taste, and palatability of a novel liquid formulation of tenapanor
TW202333703A (zh) 沃塞洛托(voxelotor)之投與方法
Weisler et al. Fed and Fasted Administration of a Novel Extended‐Release Methylphenidate Orally Disintegrating Tablet Formulation for the Treatment of ADHD
Al-Madhagi et al. Formulation of new chewable oral dosage forms of meclizine and pyridoxine hydrochloride
CN115645357A (zh) 一种拉考沙胺口服溶液处方及其制备工艺
Dixon et al. A comparison of the pharmacokinetics and tolerability of the novel antimigraine compound zolmitriptan in adolescents and adults
JP7627353B2 (ja) チザニジン液体製剤及びその用途
US12558347B2 (en) Cevimeline liquid formulations
US20250288560A1 (en) Tizanidine liquid preparation and use thereof
CN119280152A (zh) 一种地氯雷他定口服溶液及其制备方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination